Categories: Health

EssilorLuxottica: Second-Quarter and First-Half 2025 Results Conference Call Invitation

Second-Quarter and First-Half 2025 Results
Conference Call Invitation

Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer,
Mr PAUL DU SAILLANT, Deputy Chief Executive Officer,
Mr STEFANO GRASSI, Chief Financial Officer, and
Mr GIORGIO IANNELLA, Head of Investor Relations,
have the pleasure of inviting you to our Second-Quarter and First-Half 2025 Results Conference Call on:

Monday, July 28, 2025, at 6:30 pm CEST

Dial-in telephone access:

If you wish to dial into the conference call, please pre-register at the following link to receive the personal credentials (Dial-in numbers, Conference ID and User ID):

https://grid.trustwavetechnology.com/essilorluxottica/register.html

If you encounter any issue in the pre-registration phase you may contact ir@essilorluxottica.com, providing your name and surname and the name of your company.

Live webcast:

You can watch the presentation at the following link:

https://streamstudio.world-television.com/1217-2090-41873/en

The press release will be published at 6:00 pm CEST on the same day and the presentation slides will be made available prior to the call. Both can be found on https://www.essilorluxottica.com/investors.

GlobeNews Wire

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

2 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

2 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

2 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

2 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

2 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

2 hours ago